Stephen V Liu, MD· @StephenVLiu · X·· 1 天前评分70
正文 · 原文
#ESMO26 Dr. @ShaodongHong with phase II study of 1L BAT8008 (TROP2-ADC) + BAT1308 (PD1) in NSCLC. TRAEs include myelosuppression, stomatitis. RR 61% (47% in PDL1 negative, 59% in low, 83% in high). mPFS 12m (7.7m in squamous, NR for non-squamous).
88 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
2631RO按 Rapid oral 1: NSCLC, metastatic 对上
First-line BAT8008 (TROP2-ADC) plus BAT1308 (anti-PD-1) for advanced NSCLC: Results from a multicenter phase 2 study
https://esmocongress.esmo.org来源：Stephen V Liu, MD · x.com